Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Gains from Investment Securities (2016 - 2025)

Apyx Medical (APYX) has disclosed Gains from Investment Securities for 12 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 43.83% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, up 43.83%, and an annual FY2025 reading of $1.9 million, up 43.83% over the prior year.
  • Gains from Investment Securities was $1.9 million for Q4 2025 at Apyx Medical, up from $1.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.7 million in Q2 2023 and bottomed at -$2.3 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $319780.4, with a median of $5000.0 recorded in 2025.
  • Peak annual rise in Gains from Investment Securities hit 12919.05% in 2023, while the deepest fall reached 3161.84% in 2023.
  • Year by year, Gains from Investment Securities stood at -$47000.0 in 2021, then skyrocketed by 261.7% to $76000.0 in 2022, then tumbled by 3161.84% to -$2.3 million in 2023, then soared by 155.51% to $1.3 million in 2024, then soared by 43.83% to $1.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for APYX at $1.9 million in Q4 2025, $1.1 million in Q3 2025, and $5000.0 in Q2 2025.